Gut microbiota encompasses a wide variety of commensal microorganisms consisting of
trillions of bacteria, fungi, and viruses. This microbial population coexists in symbiosis with …

Nonalcoholic fatty liver disease (NAFLD) has become a serious public health issue not only
in Western countries but also in Japan. Within the wide spectrum of NAFLD, nonalcoholic …

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease
worldwide. NAFLD begins as a relatively benign hepatic steatosis which can evolve to non …

Alongside the liver, white adipose tissue (WAT) is critical in regulating systemic energy
homeostasis. Although each organ has its specialised functions, they must work …

To assess the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for
treatment of nonalcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH), we …

To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease,
affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available …

The worldwide prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to have
reached 25% or more in adults. NAFLD is prevalent in obese individuals, but may also affect …

The pathogenesis of non-alcoholic fatty liver disease, particularly the mechanisms whereby
a minority of patients develop a more severe phenotype characterised by hepatocellular …

The largest surface of the human body exposed to the external environment is the gut. At this
level, the intestinal barrier includes luminal microbes, the mucin layer, gastrointestinal …

Abstract Glucagon-like peptide-1 (GLP-1) is produced in gut endocrine cells and in the
brain, and acts through hormonal and neural pathways to regulate islet function, satiety, and …